Barr Pharmaceuticals
From Wikipedia, the free encyclopedia
| Barr Pharmaceuticals Inc | |
|---|---|
| Type | Delaware Corporation (NYSE: BRL) |
| Founded | New York (1970) |
| Headquarters | Montvale, NJ, USA |
| Key people | Bruce Downey, CEO |
| Industry | Pharmaceuticals & Medical Devices |
| Products | Generic and Proprietary Pharmaceuticals |
| Revenue | Over $1 Billion USD fiscal year 2005 |
| Employees | 2000 |
| Website | http://www.barrlabs.com |
Barr Pharmaceuticals, Inc., (NYSE: BRL) is global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company headquartered in Pomona, NY, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and Pliva d.d. and its subsidiaries. The Company markets more than 120 generic and 25 proprietary products in the U.S. and more than 550 products globally. Its core therapeutic categories include oncology (cancer drugs), female healthcare including hormone replacement and oral contraceptives, cardiovascular, anti-infective and psychotherapeutics. Barr Pharmaceuticals Inc. is a publicly traded company and member of the S&P 500. Bruce Downey is the CEO. Business Strategies > Generic Pharmaceuticals
The Company develops and markets the generic equivalent of brand pharmaceuticals. These products are marketed under the Barr Laboratories, Inc. (Barr) label. Generic development is focused on generic products that have one or more characteristics that will make it difficult for other competitors to develop competing generic products. The characteristics of the selected generic products the Company pursues may include one or more of the following:
• PRODUCT BARRIERS
- Difficult to Formulate or Manufacture
• PATENT BARRIERS
- Formulation, Raw Material, Molecule
• MARKETING BARRIERS
- Risk Management Programs, Pregnancy Registry
The Company believes that generic products with some or all of these characteristics may produce higher returns for a longer period of time than products without these characteristics.
